Senti Biosciences, Inc.
SNTI
$2.10
$0.041.94%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 37.60M | 35.74M | 34.86M | 34.36M | 35.71M |
| Gross Profit | -37.60M | -35.74M | -34.86M | -34.36M | -35.71M |
| SG&A Expenses | 25.24M | 23.48M | 20.92M | 21.58M | 22.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -178.00K | -178.00K | -178.00K | -- | -- |
| Total Operating Expenses | 62.66M | 59.04M | 55.60M | 55.93M | 58.51M |
| Operating Income | -62.66M | -59.04M | -55.60M | -55.93M | -58.51M |
| Income Before Tax | -47.58M | -58.32M | -54.79M | -52.79M | -70.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.58 | -58.32 | -54.79 | -52.79 | -70.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -28.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.58M | -58.32M | -54.79M | -52.79M | -70.90M |
| EBIT | -62.66M | -59.04M | -55.60M | -55.93M | -58.51M |
| EBITDA | -58.98M | -55.32M | -51.82M | -52.10M | -54.62M |
| EPS Basic | -4.01 | -9.62 | -11.51 | -12.75 | -15.60 |
| Normalized Basic EPS | -1.83 | -2.92 | -4.12 | -4.90 | -7.36 |
| EPS Diluted | -4.01 | -9.62 | -11.51 | -12.75 | -15.60 |
| Normalized Diluted EPS | -1.83 | -2.92 | -4.12 | -4.90 | -7.36 |
| Average Basic Shares Outstanding | 66.98M | 45.33M | 23.82M | 18.38M | 18.19M |
| Average Diluted Shares Outstanding | 66.98M | 45.33M | 23.82M | 18.38M | 18.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |